Entyvio and Humalog drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Entyvio (vedolizumab) and Humalog (insulin lispro recombinant). Common drug interactions include blood glucose increased among females and drug ineffective among males.

The phase IV clinical study analyzes what interactions people have when they take Entyvio and Humalog. It is created by eHealthMe based on reports of 26 people who take the same drugs from the FDA, and is updated regularly.

What is Entyvio?

Entyvio has active ingredients of vedolizumab. It is often used in crohn's disease. eHealthMe is studying from 23,827 Entyvio users. Check the latest studies of Entyvio.

What is Humalog?

Humalog has active ingredients of insulin lispro recombinant. It is often used in diabetes. eHealthMe is studying from 137,127 Humalog users. Check the latest studies of Humalog.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 29, 2026

26 people who take Entyvio and Humalog together, and have interactions are studied.

What are the common drug interactions of Entyvio and Humalog, by gender? *:

female:

Blood glucose increased
Constipation
Back pain
Fatigue (feeling of tiredness)
Abdominal pain
Body temperature decreased
Drug ineffective
Haematochezia (passage of stools containing blood)
Hypertension (high blood pressure)
Stress

male:

Drug ineffective
Constipation
Metastases to bone (cancer spreads to bone)
Metastases to lung (cancer spreads to lung)
Pollakiuria (abnormally frequent passage of relatively small quantities or urine)
Prostate cancer metastatic
Prostatic specific antigen increased
Renal disorder (kidney disease)
Secretion discharge
Urinary retention (the inability to completely or partially empty the bladder)

What are the common drug interactions of Entyvio and Humalog, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Blood glucose increased
Hypoglycaemic seizure (low blood sugar)

20-29:

n/a

30-39:

n/a

40-49:

Abdominal pain
Back pain
Body temperature decreased
Constipation
Haematochezia (passage of stools containing blood)
Hypertension (high blood pressure)
Polychondritis (progressive inflammation of cartilage and other connective tissue)

50-59:

Chest pain
Diarrhoea haemorrhagic (bloody diarrhoea)
Nausea (feeling of having an urge to vomit)
Rash pustular (redness with pustules)

60+:

Drug ineffective
Fatigue (feeling of tiredness)
Depression
Diarrhoea
Drug specific antibody present
Dysuria (painful or difficult urination)
Eye disorder
Eye pain
Faeces discoloured
Haematoma (collection of blood outside the blood vessels)

What are the existing conditions these people have? *

Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 8 people, 30.77%
Type 1 Diabetes: 8 people, 30.77%
Type 2 Diabetes: 4 people, 15.38%
High Blood Pressure: 4 people, 15.38%
Pain: 3 people, 11.54%
Hypersensitivity: 3 people, 11.54%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 7.69%
Blood Testosterone Increased: 2 people, 7.69%
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (long lasting infection of nerves outside brain and spinal cord): 2 people, 7.69%
Depression: 2 people, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Entyvio and Humalog?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously